US 11,851,678 B2
Methods for producing genetically engineered cell compositions and related compositions
Mirna Mujacic, Seattle, WA (US); and Ayu Rahardjo, Kirkland, WA (US)
Assigned to Juno Therapeutics, Inc., Seattle, WA (US)
Appl. No. 16/637,709
Filed by Juno Therapeutics, Inc., Seattle, WA (US)
PCT Filed Aug. 9, 2018, PCT No. PCT/US2018/046149
§ 371(c)(1), (2) Date Feb. 7, 2020,
PCT Pub. No. WO2019/032927, PCT Pub. Date Feb. 14, 2019.
Claims priority of provisional application 62/596,770, filed on Dec. 8, 2017.
Claims priority of provisional application 62/543,363, filed on Aug. 9, 2017.
Prior Publication US 2020/0181575 A1, Jun. 11, 2020
Int. Cl. A61K 35/17 (2015.01); A61K 38/19 (2006.01); C12N 5/0783 (2010.01); A61K 38/20 (2006.01); C07K 14/705 (2006.01); C12N 7/00 (2006.01); C12N 15/86 (2006.01); G01N 33/569 (2006.01)
CPC C12N 5/0636 (2013.01) [A61K 35/17 (2013.01); C12N 7/00 (2013.01); C12N 15/86 (2013.01); G01N 33/56972 (2013.01); C12N 2502/1114 (2013.01); C12N 2740/13043 (2013.01); C12N 2740/15043 (2013.01); G01N 2333/70514 (2013.01); G01N 2333/70517 (2013.01)] 38 Claims
 
1. A method for generating a cell composition, the method comprising:
(a) combining a first cell composition comprising naïve-like CD4+ T cells with a second cell composition comprising naïve-like CD8+ T cells to produce an input cell composition in which the ratio of the naïve-like CD4+ T cells to the naïve-like CD8+ T cells in the input composition is between or about between 0.8:1 and 2.2:1, inclusive;
wherein the ratio has been determined based on the number, number per volume, number per weight, or percentage of naïve-like CD4+ T cells in the first cell composition and the number, number per volume, number per weight, or percentage of naïve-like CD8+ T cells in the second cell composition,
wherein the naïve-like CD4+ cells:
(i) are surface positive for CD45RA and CCR7;
(ii) are surface positive CD27 and CCR7; or
(iii) are surface positive for CCR7 and surface negative for CD62L; and
wherein the naïve-like CD8+ cells:
(i) are surface positive for CD45RA and CCR7;
(ii) are surface positive CD27 and CCR7; or
(iii) are surface positive for CCR7 and surface negative for CD62L; and
(b) contacting the input cell composition with an agent comprising a nucleic acid molecule encoding a recombinant receptor under conditions to introduce the nucleic acid molecule encoding the recombinant receptor into the input cell composition.